Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon beta-1b biosimilar - Primrose Bio

Next Previous
Drug Profile

Peginterferon beta-1b biosimilar - Primrose Bio

Alternative Names: PF-726

Latest Information Update: 22 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfenex - Agila Biotech (JV)
  • Developer Primrose Bio
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
  • 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for research development in Multiple-sclerosis in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top